Dan-Yun Ruan
Overview
Explore the profile of Dan-Yun Ruan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
756
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ruan D, Huang W, Li Y, Zhao Y, Shi Y, Jia Y, et al.
Signal Transduct Target Ther
. 2025 Feb;
10(1):62.
PMID: 40016191
HA121-28, a promising multikinase inhibitor, mainly targets rearranged during transfection (RET) fusions and selectively targets vascular endothelial growth factor receptor-2, endothelial growth factor receptor, and fibroblast growth factor receptor 1-3....
2.
Wei X, Wu H, Ruan D, Wang F, Xu L, Li Y, et al.
Cell Rep Med
. 2025 Feb;
6(2):101969.
PMID: 39970877
DX1002 is an oral vascular-disrupting agent and exhibits promising results in preclinical studies, leading to tumor vasculature destruction and xenografted tumor necrosis in various animal models. In the phase 1...
3.
Ruan D, Li T, Wang Y, Meng Q, Li Y, Yu K, et al.
Oncogene
. 2025 Feb;
44(8):558.
PMID: 39905122
No abstract available.
4.
Ruan D, Liu F, Wei X, Luo S, Zhuang Z, Wang Z, et al.
Lancet Oncol
. 2025 Jan;
26(2):227-238.
PMID: 39788133
Background: CMG901 is a novel first-in-class antibody-drug conjugate with a humanised anticlaudin 18.2 antibody linked to microtubule-disrupting agent monomethyl auristatin E. We aimed to assess the antitumour activity and safety...
5.
Ruan D, Wei X, Liu F, Hu X, Zhang J, Ji D, et al.
J Hematol Oncol
. 2024 Nov;
17(1):118.
PMID: 39614368
Background: There is an unmet clinical need to enhance the response rate and safety of anti-PD-1/PD-L1-based cancer immunotherapy (IO). Herein, we presented the clinical study of IBI318 (LY3434172), a first-in-class...
6.
Wang F, Ruan D, Xu R
Cell
. 2024 Mar;
187(7):1578-1583.
PMID: 38552607
As one of the world's most populous countries, China bears a heavy burden and a broad spectrum of cancers, including unique types, providing a unique environment for drug research and...
7.
Ruan D, Wu H, Meng Q, Xu R
Cancer Commun (Lond)
. 2023 Dec;
44(1):3-22.
PMID: 38159059
In recent years, remarkable breakthroughs have been reported on antibody-drug conjugates (ADCs), with 15 ADCs successfully entering the market over the past decade. This substantial development has positioned ADCs as...
8.
Xu Y, Li T, Shen A, Bao X, Lin J, Guo L, et al.
Clin Transl Med
. 2023 Dec;
13(12):e1505.
PMID: 38082402
Background: Epstein-Barr virus-associated gastric cancer (EBVaGC) is regarded as a distinct molecular subtype of GC, accounting for approximately 9% of all GC cases. Clinically, EBVaGC patients are found to have...
9.
Targeting the cholesterol-RORα/γ axis inhibits colorectal cancer progression through degrading c-myc
Wang Y, Ruan D, Wang Z, Yu K, Rong D, Liu Z, et al.
Oncogene
. 2022 Nov;
41(49):5266-5278.
PMID: 36316442
Dysregulated cholesterol metabolism is a hallmark of colorectal cancer (CRC). However, the usage of cholesterol-lowering agents seemed to have no benefit in CRC patients. In this study, we focused on...
10.
Ruan D, Chen Y, Wei X, Wang Y, Wang Z, Wu H, et al.
Gastroenterol Rep (Oxf)
. 2021 Dec;
9(6):560-570.
PMID: 34925853
Background: Due to its limited efficacy and potential toxicity, anti-PD-1 monoclonal antibody is not suitable for all advanced gastric cancer (AGC) patients and predictive biomarkers identifying patients who can benefit...